TechCrunch: NeuraLight Launches from Stealth to Digitize Neurology

Digitizing Neurology

We are building an AI-driven platform to accelerate and improve drug development, monitoring, and care for patients with neurological disorders using information captured with a standard smartphone or webcam.


Over 1 billion people worldwide suffer from neurological disorders, making them the leading cause of global disability.

Presently, neurological evaluation is highly subjective, non-sensitive, and depends on manual examination of symptoms. This poses a significant challenge for treatment development and precision care.

Our Mission

We want to transform the lives of the billions of people impacted by neurological disorders by digitizing evaluation and care.

Our vision is a world where neurological disorders can be prevented, diagnosed, and treated effectively, and people live longer, healthier lives.

icon Scope

This challenge applies to a wide scope of neurological disorders, including Alzheimer's, Parkinson's Disease, and Multiple Sclerosis, among others.


icon Our Solution

Our AI-driven platform automatically extracts micro-oculometrics, providing objective and sensitive digital markers for neurological disorders.


icon Our Impact

Our solution will serve as a robust proxy for currently used endpoints, and ultimately define a new measurement standard, paving the path for precision medicine in neurology.

Technology & IP

Our platform is powered by proprietary patent-pending Computer Vision and Deep Learning algorithms to attain sub‑pixel resolution using just a standard smartphone or webcam.

We are building the world’s largest, proprietary, de-identified oculometric database. We then apply AI to surface big data insights to empower true personalization in neurological care.

The Science

Over 750 papers have been published on the correlation between oculometrics and neurological disorders including in the very top journals (Lancet, Nature, Brain, Neurology, Multiple Sclerosis Journal, and others).

We are working with some of the worlds greatest minds including Nobel laureates to take this science one step further, and establish more robust models and accurate endpoints.

Our Team

We are a team of scientists, entrepreneurs, and dreamers who are building the platform that will digitize neurological evaluation and care.


Micha Breakstone, PhD

CEO & Co-Founder

Micha Breakstone is a repeat entrepreneur who was previously Co-Founder and President of (acquired for $575m by ZoomInfo). Before that he sold his NLP business unit to Intel in 2014, and helped build several Israeli unicorns “from the outside”. He has broad experience designing Machine Learning systems, and holds a Masters in Math, and a PhD in Cognitive Science.


Edmund Benami

CTO & Co-Founder

Eddy is a repeat entrepreneur and an award-winning mathematician, with over 20 years of experience designing novel AI algorithms, and building world class teams to take on some of the most challenging technological challenges in signal processing, computer vision, and AI.


Rivka Kreitman, PhD

Chief Innovation Officer

Rivka is a Pharmaceutical Executive, and has spent over 26 years at Teva during which she held various roles including Head of Global Innovative Research and Development (IR&D), managing a group of 700 researchers focusing i.a. on CNS and Autoimmune. Rivka has also led Search and Evaluation, and was Head of Global Speciality Regulatory Affairs. Rivka earned her PhD at the Weizmann Institute of Science (Biochemistry) and postdoctoral work at Princeton University (Molecular Biology).


Vova Anisimov

Head of Engineering

Vova has over 10 years of experience in high performance computing, Machine Learning, scientific computing, and development of large scale systems. Vova began his career in an elite Israeli Intelligence Unit. Prior to joining Neuralight, Vova was at Google working on high impact social projects: Flood Forecasting and Care Studio. Vova holds a BSc in Mathematics from Tel Aviv University which he completed during high school.


Jonathan Soberg, Director

MS&AD Ventures

Jon Soberg is Managing Partner at MS&AD Ventures, an early-stage venture capital firm focused on the future of finance, risk assessment, and building a sustainable society. Jon has made over 120 investments across 5 continents and has held more than 40 board positions. Prior to becoming an investor, Jon was a serial entrepreneur and operator, with an IPO exit at Adforce. Jon has a Master's degree in Engineering, a CFA, and is an MBA and Palmer Scholar at Wharton. Jon is ranked #13 on Business Insider's Seed 100 list of top seed investors.


Elias Davis, Director

Kli Capital

Former Googler and startup operator turned early-stage investor with Kli Capital, Elias has backed, supported, and been a champion for industry-defining founders at companies including Nym Health, Imagen, mPharma, Lumen, Digi-prex, Visibly, and Gainful, amongst others outside of digital health. Elias is driven by impact and believes in building long-term relationships, spanning well beyond the life-cycle of any single company.


David Citron, Observer

Global Founders Capital

David Citron is an early stage investor with Global Founders Capital. For the past 10 years David has been fortunate enough to invest in amazing entrepreneurs from a variety of backgrounds, tackling the world's biggest problems head on using cutting edge technology.


Prashant Fonseka, Observer

Tuesday Capital

Prashant Fonseka is a Partner at Tuesday Capital, where he leads pre-seed and seed investments in consumer, enterprise, and frontier technology. Prashant is a gearhead and pilot who started his first businesses before college, graduated Magna Cum Laude from Claremont McKenna College, and served as a Teach for America corps member before joining Tuesday Capital in 2013.


Tamara Minick-Scokalo, Observer

Next Ventures

Board director Avast. Former P&G executive. Co-founder and first CEO and Chairwoman at Trax retail, Partner at Next Ventures.


Gil Shklarski, PhD

Gil is a startup investor, advisor, and mentor to founders and technical leaders. Previously, Gil has been Flatiron Health's CTO growing the technology team from two engineers to a team of over 350 across software, DevOps, IT, security, product design, and data science.


Prof. Alvin Roth

Al Roth is a professor of Economics at Stanford University. He’s worked widely on market design, including in health care, for which he won the 2012 Nobel Prize in Economics.


Prof. Ruth Djaldetti

Head of The Movement Disorder Center, Rabin Medical Center, Prof. at TAU Medical School, Research fellowship, Columbia University, world-renowned neurologist & researcher.


Marta Bralic Kerns

Marta Bralic Kerns is the Founder & CEO of Pomelo Care, a company transforming maternity and neonatal outcomes through personalized, evidence-based care for moms and babies. Previously, Marta was the Senior Vice President of Business Development at Flatiron Health - the leader in oncology real world evidence - where she led strategic partnerships, corp dev, and new product initiatives. Marta started her career in McKinsey's healthcare practice working on healthcare payment reform after graduating magna cum laude from Harvard with a degree in Government and Computer Science.


Afik Gal, MD, MBA

Afik has over 20 years of experience in healthcare analytics, entrepreneurship and innovation leadership (e.g. head of the innovation lab at PwC’s healthcare advisory), and earned his MBA from Duke University and an MD from Ben-Gurion University. Afik is a co-founder of VC-backed Assured Allies, an insur-tech company dedicated to making longevity sustainable.


Prof. Fred Lublin

Prof. Fred Lublin is a world renowned authority on the treatment of MS, whose work has redefined the clinical course definitions of MS. Prof. Lublin serves as Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center. As a paid consultant and shareholder he advises us on designing digital markers for MS and its progression.


Prof. Thomas C. Südhof, M.D.

Prof. Südhof is a world-renowned neuroscientist who won a Nobel prize for his work on synaptic transmission. Currently heading the Südhof lab at Stanford, he's considered by many one of the world's leading researchers of Alzheimer's Disease.

Selected Investors